Kalamazoo, MI, United States of America

Charles H Spilman


Average Co-Inventor Count = 2.1

ph-index = 3

Forward Citations = 47(Granted Patents)


Company Filing History:


Years Active: 1993-1997

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Charles H Spilman: Innovator in Atherosclerosis Treatment

Introduction

Charles H Spilman is a notable inventor based in Kalamazoo, MI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds useful for treating atherosclerosis and hypercholesterolemia. With a total of 5 patents to his name, Spilman's work has had a meaningful impact on medical science.

Latest Patents

Among his latest patents, Spilman has developed pyrazoloazepino substituted oximes that are beneficial in combating atherosclerosis. These compounds are characterized by the formula ##STR1##, where R is ##STR2##, and R.sup.5 is --(CH.sub.2).sub.c -- with c ranging from 3 to 6. Additionally, he has worked on pyridino substituted oximes and imidazopyridino- and pyrazolopyridino- substituted oximes, which are also aimed at treating atherosclerosis and hypercholesterolemia.

Career Highlights

Spilman is associated with The Upjohn Company, where he has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approaches have led to the creation of effective treatments that address critical health issues.

Collaborations

Throughout his career, Spilman has collaborated with esteemed colleagues such as Scott D Larsen and Vincent E McCurdy. These partnerships have fostered a collaborative environment that enhances the quality and scope of their research.

Conclusion

Charles H Spilman stands out as a dedicated inventor whose work in pharmaceuticals has contributed to significant advancements in the treatment of atherosclerosis. His innovative spirit and collaborative efforts continue to inspire progress in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…